Axsome Therapeutics AXSM Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's total liabilities & equity?
- Axsome Therapeutics (AXSM) reported total liabilities & equity of $713.61M in Q1 2026.
- How has Axsome Therapeutics's total liabilities & equity changed year-over-year?
- Axsome Therapeutics's total liabilities & equity increased by 19.6% year-over-year, from $596.67M to $713.61M.
- What is the long-term trend for Axsome Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), Axsome Therapeutics's total liabilities & equity has grown at a 30.0% compound annual growth rate (CAGR), from $186.13M to $689.81M.
- What does total liabilities & equity mean?
- The total size of the company's balance sheet, representing all assets financed by debt or equity.
- How do you interpret total liabilities & equity?
- Growth in this figure generally indicates an expansion of the company's asset base and operational footprint.
- How does total liabilities & equity compare across companies?
- Used as a baseline for scaling other financial ratios across the industry.